C0250: Prolongation of Enoxaparin Therapy to One Month Improves Recanalization of Occlusive Thrombosed Deep Veins

Evaluation of the deep vein recanalisation and function after low molecular weight heparin (calcium nadroparine) therapy of deep vein thrombosis. Preliminary report

“…Nowadays, the ambulatory treatment of VTE is fully accepted by the medical societies of many Western European countries, and is administered to up to 80% of patients with venous thrombosis and 50% of patients with pulmonary embolism [20]. The newly published papers indicate the role of LMWH in the recanalisation of the thrombotic veins and the reduction of valvular incompetence rate, secondary to venous thrombosis [21][22][23][24][25][26][27][28][29].…”

“…The literature data suggests that the treatment with LMWH is associated with less episodes of VTE recurrence, pulmonary embolism, deaths with concomitant lower risk of complications and with better recanalisation rate of thrombosed deep vein segments and preservation of valvular function [15,20,[25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42].…”

Anticoagulant therapy of venous thromboembolic complications: problems and perspectives

“…В то же время, у 20% больных, получивших НФГ и варфарин, река-нализация окклюзий не произошла и через 12 меся-цев лечения. Однофакторный анализ показал, что продление терапии эноксапарином до одного месяца в 2,5 раза увеличивает вероятность реканализации окклюзий в течение 12 месяцев антикоагулянтной терапии (относительная вероятность 2,52; 95% ДИ 1,06-5,97; р=0,036) [12,14].…”